A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: An NCIC clinical trials group study

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 335-340

  Biagi, J J ^a   Oza, A M ^b   ChalChal, H I ^c   Grimshaw, R ^d   Ellard, S L ^e   Lee, U ^e   Hirte, H ^f   Sederias, J ^g   Ivy, S P ^h   Eisenhauer, E A ^g  

^a Cancer Centre of South Eastern Ontario   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c Allan Blair Cancer Centre   (Canada)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f JURAVINSKI CANCER CENTRE   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Clinical trial; Recurrent ovarian cancer; Sunitinib; Targeted therapy

Indexed keywords

CA 125 ANTIGEN; PLATINUM COMPLEX; SUNITINIB;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ASCITES; ASCITES FLUID; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; LEUKOCYTE; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NAUSEA; OVARY ADENOCARCINOMA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; SKIN DISCOLORATION; TASTE DISORDER; THROMBOCYTE; TUMOR REGRESSION; UTERINE TUBE CARCINOMA;

EID: 79251585977     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq357     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2008. Toronto, Canada 2008.
3. Covens A, Carey M, Bryson P et al. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002; 85: 71-80.
4. Thigpen T, Stuart G, du Bois A et al. Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens. Ann Oncol 2005; 16 (Suppl. 8): viii13-viii19.
5. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
6. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364.
8. Bamberger ES, Perrett CW. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002; 55: 348-359.
9. Matei D, Emerson RE, Lai YC et al. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene 2006; 25: 2060-2069.
10. Yamamoto S, Konishi I, Mandai M et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 1997; 76: 1221-1227.
11. Burger RA, Sill MW, Monk BJ et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 5165-5171.
12. Garcia AA, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26: 76-82.
13. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005; 96: 902-905.
14. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
15. Abrams TJ, Murray LJ, Pesenti E et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2: 1011-1021.
16. Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther 2003; 2: 471-478.
17. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35.
18. Rosen L, Mulay M, Long J et al. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. J Clin Oncol 2003; 22: 191s (Abstr 765).
19. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338.
20. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16-24.
21. Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816.
22. Socinski MA, Novello S, Brahmer JR et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650-656.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
24. Rustin GJ, Quinn M, Thigpen T et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96: 487-488.
25. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
26. Cannistra SA, Matulonis UA, Penson RT et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25: 5180-5186.
27. Hirte H, Vidal L, Fleming GF et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008; 26: 298s (Abstr 5521).
28. Economidou F, Antoniou KM, Tzanakis N et al. Angiogenic molecule Tie-2 and VEGF in the pathogenesis of pleural effusions. Respir Med 2008; 102: 774-779.
29. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.